X

Trial Profile

Heterologous Prime-boost-boost Vaccine Combinations for Long-term Humoral and Cellular Immunity Against COVID-19

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 21 Oct 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs BBV 152 (Primary) ; COVID-19 vaccine adjuvanted Novavax (Primary) ; Elasomeran (Primary) ; Tozinameran (Primary)
Indications COVID 2019 infections
Focus Pharmacodynamics
Acronyms PRIBIVAC

Most Recent Events

14 Oct 2024 Protocol has been amended ; Non-mRNA booster vaccine C removed from study protocol, study arm changed from 5 to 4.
14 Oct 2024 Status changed from recruiting to completed.
16 Jun 2022 Study design published in the Trials.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com